{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:41:03Z","timestamp":1788795663332,"version":"build-2803163510"},"reference-count":29,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,7,30]]},"DOI":"10.1536\/ihj.22-003","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T18:11:25Z","timestamp":1657735885000},"page":"661-668","source":"Crossref","is-referenced-by-count":10,"title":["Vascular Endothelial Dysfunction in Myeloproliferative Neoplasms and Gene Mutations"],"prefix":"10.1536","volume":"63","author":[{"given":"Rie","family":"Aoyama","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"},{"name":"Division of Cardiology, Heart and Vascular Institute, Funabashi Municipal Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Tara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Wakita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Baxter EJ, Scott LM, Campbell PJ, <i>et al<\/i>. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. James C, Ugo V, Le Cou\u00e9dic JP, <i>et al<\/i>. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8.","DOI":"10.1038\/nature03546"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kralovics R, Teo SS, Buser AS, <i>et al<\/i>. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106: 3374-6.","DOI":"10.1182\/blood-2005-05-1889"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tefferi A, Pardanani A. Myeloproliferative neoplasms: A contemporary review. JAMA Oncol 2015; 1: 97-105.","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","volume":"19","year":"2019","unstructured":"5. Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer 2019; 19: 184.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Austin SK, Lambert JR. The JAK2 V617F mutation and thrombosis. Br J Haematol 2008; 143: 307-20.","DOI":"10.1111\/j.1365-2141.2008.07258.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-20.","DOI":"10.1055\/s-2007-976165"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Castiglione M, Jiang YP, Mazzeo C, <i>et al<\/i>. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. J Thromb Haemost 2020; 18: 3359-70.","DOI":"10.1111\/jth.15095"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Okabe M, Yamaguchi H, Usuki K, <i>et al<\/i>. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L\/K mutations. Leuk Res 2016; 40: 68-76.","DOI":"10.1016\/j.leukres.2015.11.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nangalia J, Massie CE, Baxter EJ, <i>et al<\/i>. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-405.","DOI":"10.1056\/NEJMoa1312542"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cella G, Marchetti M, Vianello F, <i>et al<\/i>. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 2010; 104: 151-6.","DOI":"10.1160\/TH09-09-0663"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Arber DA, Orazi A, Hasserjian R, <i>et al<\/i>. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Corretti MC, Anderson TJ, Benjamin EJ, <i>et al<\/i>. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.","DOI":"10.1016\/S0735-1097(01)01746-6"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Tefferi A, Rumi E, Finazzi G, <i>et al<\/i>. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27: 1874-81.","DOI":"10.1038\/leu.2013.163"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005; 42: 206-20.","DOI":"10.1053\/j.seminhematol.2005.08.003"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Passamonti F, Thiele J, Girodon F, <i>et al<\/i>. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197-201.","DOI":"10.1182\/blood-2012-01-403279"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Barbui T, Finazzi G, Carobbio A, <i>et al<\/i>. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128-33.","DOI":"10.1182\/blood-2012-07-444067"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, <i>et al<\/i>. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: A population-based cohort study. Ann Intern Med 2018; 168: 317-25.","DOI":"10.7326\/M17-0028"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Guy A, Poisson J, James C. Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms. Leukemia 2021; 35: 935-55.","DOI":"10.1038\/s41375-021-01170-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Marchioli R, Finazzi G, Landolfi R, <i>et al<\/i>. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-32.","DOI":"10.1200\/JCO.2005.07.062"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2019; 2019: 397-406.","DOI":"10.1182\/hematology.2019001318"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 2017; 135: 1075-92.","DOI":"10.1161\/CIRCULATIONAHA.116.024534"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. P\u00f3sfai \u00c9, Marton I, Borb\u00e9nyi Z, Nemes A. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. Anatol J Cardiol 2016; 16: 397-402.","DOI":"10.14744\/AnatolJCardiol.2015.6125"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Arellano-Rodrigo E, Alvarez-Larr\u00e1n A, Reverter JC, <i>et al<\/i>. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009; 84: 102-8.","DOI":"10.1002\/ajh.21338"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Poisson J, Tanguy M, Davy H, <i>et al<\/i>. Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. J Clin Invest 2020; 130: 2630-43.","DOI":"10.1172\/JCI124566"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Rumi E, Pietra D, Ferretti V, <i>et al<\/i>. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544-51.","DOI":"10.1182\/blood-2013-11-539098"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Misawa K, Yasuda H, Araki M, <i>et al<\/i>. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 2018; 107: 673-80.","DOI":"10.1007\/s12185-018-2421-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Agewall S, Beltrame JF, Reynolds HR, <i>et al<\/i>. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J 2017; 38: 143-53.","DOI":"10.1093\/eurheartj\/ehw149"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Neunteufl T, Heher S, Stefenelli T, Pabinger I, Gisslinger H. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001; 115: 354-9.","DOI":"10.1046\/j.1365-2141.2001.03092.x"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/4\/63_22-003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T01:25:21Z","timestamp":1715217921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/4\/63_22-003\/_article"}},"subtitle":["A Possible Cause of Coronary Artery Spasm"],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.22-003","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"article-number":"22-003"}}